Get the Stockscreener App
1.94
19.83%
-0.48
iBio Inc stock is traded at $1.94, with a volume of 8.05M.
It is down -19.83% in the last 24 hours and up +55.20% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$2.42
Open:
$2.35
24h Volume:
8.05M
Relative Volume:
1.21
Market Cap:
$43.63M
Revenue:
$2.05M
Net Income/Loss:
$-23.15M
P/E Ratio:
-0.2925
EPS:
-6.6319
Net Cash Flow:
$-16.93M
1W Performance:
+61.67%
1M Performance:
+55.20%
6M Performance:
+88.35%
1Y Performance:
-22.71%
1-Day Range:
$1.83
$2.375
1-Week Range:
$1.54
$3.82
52-Week Range:
$0.5562
$6.8908
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.94 | 54.42M | 2.05M | -23.15M | -16.93M | -6.6319 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Oppenheimer | Outperform |
| Oct-17-25 | Initiated | Leerink Partners | Outperform |
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
View All
iBio Inc Stock (IBIO) Latest News
Best Penny Stocks To ConsiderDecember 10th - MarketBeat
iBio: Obesity Solutions to Drive Stock Momentum - StocksToTrade
Biotech Alert: Searches spiking for these stocks today - TipRanks
3 Penny Stocks to Watch Now, 12/9/25 - TipRanks
iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025) - ts2.tech
Analyst Upgrade: Will iBio Inc stock outperform international peersQuarterly Trade Review & Accurate Intraday Trading Signals - moha.gov.vn
iBio Rockets: Is It a Mirage or Real Boost? - StocksToTrade
Best Biotech Stocks To Keep An Eye OnDecember 8th - MarketBeat
iBio’s New Approach: Game Changer or Just Artifice? - timothysykes.com
iBio (IBIO) Price Target Increased by 14.56% to 4.81 - Nasdaq
Can iBio Inc. stock sustain free cash flow growthJuly 2025 Highlights & Technical Entry and Exit Alerts - Newser
Is iBio Inc. (0JV0) stock a fit for income portfoliosQuarterly Market Review & Daily Profit Maximizing Trade Tips - Newser
IBIO: Long-acting antibody pipeline targets obesity gaps, with IND filings and first-in-human trials ahead - TradingView
Will iBio Inc. (0JV0) stock test record highs in 2025Weekly Risk Summary & Proven Capital Preservation Tips - Newser
IBIO: AI-driven antibody programs target obesity gaps with IND filings and first-in-human trials ahead - TradingView
Can iBio Inc. stock deliver sustainable ROE2025 Volume Leaders & High Conviction Investment Ideas - Newser
How iBio Inc. stock reacts to oil pricesMarket Movement Recap & High Accuracy Swing Entry Alerts - Newser
Why iBio Inc. (0JV0) stock could rally strongly2025 Bull vs Bear & Safe Capital Growth Tips - Newser
Why iBio Inc. (0JV0) stock trades below fair valueLayoff News & Free Weekly Chart Analysis and Trade Guides - Newser
How iBio Inc. (0JV0) stock responds to job market shiftsEarnings Recap Report & Low Risk High Win Rate Stock Picks - Newser
Why analysts raise outlook for iBio Inc. (0JV0) stockJuly 2025 Momentum & Fast Gain Swing Alerts - Newser
Aug Patterns: Should I hold or sell iBio Inc stock in 2025New Guidance & Proven Capital Preservation Tips - BỘ NỘI VỤ
iBio (IBIO) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Why retail traders accumulate iBio Inc. (0JV0) stockJuly 2025 Breakouts & Verified Entry Point Signals - Newser
How robust is iBio Inc. (0JV0) stock financial positionJuly 2025 Decliners & Precise Entry and Exit Recommendations - Newser
Activity Recap: How institutional buying supports iBio Inc. stockJuly 2025 Final Week & AI Driven Stock Reports - moha.gov.vn
iBio, Inc. Reports Q3 2025 Financial Results - MSN
What technical charts say about iBio Inc. stockQuarterly Earnings Report & Long-Term Safe Investment Plans - moha.gov.vn
How institutional buying supports iBio Inc. stockPortfolio Gains Summary & Stepwise Trade Execution Plans - BỘ NỘI VỤ
iBio to Participate in the 8th Annual Evercore Healthcare Conference - The Manila Times
[Form 4] iBio, Inc. Insider Trading Activity - Stock Titan
IBIO Form 4 shows director awarded 13,500 options at $1 - Stock Titan
IBIO Form 4: Director awarded 13,500 stock options at $1 - Stock Titan
iBio Form 4 shows director award of 13,500 stock options - Stock Titan
iBio shareholders elect directors and approve annual meeting proposals By Investing.com - Investing.com Canada
iBio Confirms Directors and Auditor at Annual Meeting - TipRanks
iBio shareholders elect directors and approve annual meeting proposals - Investing.com
[8-K] iBio, Inc. Reports Material Event | IBIO SEC FilingForm 8-K - Stock Titan
Can trapped investors hope for a rebound in iBio Inc.2025 Market Sentiment & Weekly High Return Opportunities - newser.com
iBio, Inc. (IBIO) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Is iBio Inc. stock safe for conservative investors2025 Big Picture & Real-Time Price Movement Reports - newser.com
Why hedge funds are buying iBio Inc. stockJuly 2025 News Drivers & High Accuracy Investment Signals - newser.com
Will iBio Inc. stock deliver better than expected guidanceMarket Volume Summary & Stock Portfolio Risk Management - newser.com
Is iBio Inc. (0JV0) stock supported by free cash flowJuly 2025 Patterns & Expert Curated Trade Setups - newser.com
Why iBio Inc. stock is rated strong buyTrade Risk Summary & Daily Stock Trend Watchlist - newser.com
Why iBio Inc. stock appeals to dividend seekersJuly 2025 Patterns & Verified Chart Pattern Trade Signals - newser.com
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):